Staff Reports
Governor JB Pritzker says he lost about 80 pounds after a Type 2 diabetes diagnosis by taking a GLP‑1 medication and changing his diet and exercise. That’s a big personal health win if true. But when state insurance pays for costly drugs and the governor’s own disclosure lands in the middle of a campaign season, the story stops being private and starts to look like a budget and political question.
Pritzker’s story: 80 pounds, fewer injections, and a message
In interviews with CBS Mornings and the Chicago Sun‑Times, Governor JB Pritzker said he has been on a GLP‑1 medication for roughly two years and that he started weekly injections in the spring of 2024. He told reporters he’s come off insulin and that, quote, “I feel a whole lot different and a whole lot better.” He also defended the state’s decision to cover GLP‑1 drugs for eligible employees and pushed back on suggestions this was image management ahead of any national plans. And yes, he told interviewers, “I don’t think it’s cheating. I think it’s what I need to succeed.”
Policy and price: Who pays for GLP‑1 drugs in Illinois?
Here’s where the personal meets the public. Illinois expanded group health coverage to include GLP‑1 drugs — names you’ve heard like Wegovy, Ozempic, Mounjaro — for eligible state workers. Reports put that coverage at roughly 55,000 employees and estimate the cost to the state in the hundreds of millions, with about $147 million cited for fiscal year 2025. Pritzker rightly points out the coverage predated his own use, but taxpayers still have a right to ask whether state government should be on the hook for long‑term, expensive weight‑loss drugs that can require ongoing treatment.
GLP‑1 medicines: effective, medical, and not without trade-offs
GLP‑1 receptor agonists were developed to treat Type 2 diabetes and do help many patients lose weight by lowering appetite and boosting insulin response. They can be powerful tools when used with diet and exercise. But they are prescription medicines. The FDA and doctors warn about side effects like nausea and other gastrointestinal problems, and clinical experience shows weight often returns if the drug is stopped. These are not miracle quick fixes — they are medical treatments that need supervision and clear cost‑benefit thinking when public money is involved.
Politics, optics, and accountability
This disclosure did not happen in a vacuum. Pritzker is running for reelection as governor, faces public mockery over his weight from national figures, and has been the subject of speculation about future ambitions. He insists he has no announcements on running for higher office and that he is focused on governing. Fair enough. But voters should expect transparency: why the state insurance plan covers these drugs, how much the coverage really costs, and what guardrails exist to prevent open‑ended spending. If this program truly saves money by preventing costly diabetes care, show the math. If it doesn’t, taxpayers deserve better choices.
At the end of the day, a governor getting healthier is good news. But when personal medicine meets public funds and political timing, citizens have a duty to ask hard questions. Illinois should treat GLP‑1 coverage like any other costly public benefit — with clear rules, budgets, and accountability — not as a PR talking point for the next campaign ad.
